← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics / Bristol Myers Squibb

Traditional approvalTraditional conversionFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after two or more prior systemic therapy lines. FDA converted this accelerated indication to traditional approval.

LAMPGEN ANALYSIS

Why it matters

The conversion confirms the regulatory status of the follicular lymphoma indication. Keep the evidence for this use separate from Breyanzi’s other lymphoma indications.

What research teams should watch

Document histology and prior therapy lines, and account for referral, cell collection and treatment-center capacity when discussing access.

PRIMARY RECORDS

Sources